Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 American Cancer Society, 2020 Huggins, 1941, Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Am Assoc Cancer Res, 1, 293 Perlmutter, 2007, Androgen deprivation therapy in the treatment of advanced prostate cancer, Rev Urol, 9, S3 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396 Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657 Kennedy-Martin, 2015, A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results, Trials, 16, 495, 10.1186/s13063-015-1023-4 O’Shea, 2020, Pelvic lymph nodes and pathways of disease spread in male pelvic malignancies, Abdom Radiol (NY), 45, 2198, 10.1007/s00261-019-02285-9 Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Moeyart, 2016, Reliability, validity, and usability of data extraction programs for single-case research designs, Behav Modif, 40, 874, 10.1177/0145445516645763 Parker, 2020, Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 31, 1119, 10.1016/j.annonc.2020.06.011 Ventzel, 2018, Chronic pain and neuropathy following adjuvant chemotherapy, Pain Med, 19, 1813, 10.1093/pm/pnx231 Eckhoff, 2015, Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors, Eur J Cancer, 51, 292, 10.1016/j.ejca.2014.11.024 Ewertz, 2015, Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives, Acta Oncol, 54, 587, 10.3109/0284186X.2014.995775 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 McNamara, 2018, The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation, Prostate Cancer Prostatic Dis, 21, 306, 10.1038/s41391-017-0014-9 Wallis, 2018, Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis, Eur Urol, 73, 834, 10.1016/j.eururo.2017.10.002 Iacovelli, 2018, The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer, Clin Genitourin Cancer, 16, e645, 10.1016/j.clgc.2017.12.007 Rydzewska, 2017, Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis, Eur J Cancer, 84, 88, 10.1016/j.ejca.2017.07.003